InventHelp Inventor Develops Accessory for Sanitizing Toilet Seats (NPL-349)
- S&P 500, Dow climb for third day and close at records
- Tesla (TSLA) China Numbers 'Robust' - Wedbush
- Apple (AAPL) Shares Seen as 'Attractive' as Recent Checks Show Continuously Strong Demand - Citi
- Amazon.com warehouse workers vote to reject forming union in Alabama
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
PITTSBURGH, March 16, 2021 /PRNewswire/ -- "I was concerned about sanitation and hygiene, especially when using public toilets," said an inventor, from Naples, Fla., "so I invented the SANI-SEAT. My design ensures that a toilet seat is properly sanitized before and after use to reduce contact with germs and bacteria."
The patent-pending invention provides an effective way to clean a toilet seat. In doing so, it eliminates the hassle and mess associated with manually cleaning the toilet seat. As a result, it saves time and effort and it increases sanitation. The invention features a practical design that is easy to apply and use so it is ideal for households and public restrooms. Additionally, it is producible in design variations and a prototype is available.
The original design was submitted to the Naples sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 19-NPL-349, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission Services at http://www.InventHelp.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/inventhelp-inventor-develops-accessory-for-sanitizing-toilet-seats-npl-349-301246004.html
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gracell Biotechnologies Reports Long-term Follow-up Data on TruUCAR-enabled GC027 in Relapsed/Refractory T-ALL at the AACR 2021 Annual Meeting
- Cardiff Oncology in Collaboration with MIT Presents Gene Signature Analyses Data Identifying Androgen-Independent Mechanism for Onvansertib-Abiraterone Synergy in mCRPC
- Cardiff Oncology Presents Findings from its Expanded Access Program Highlighting the Clinical Benefit of Onvansertib in Heavily Pretreated Patients with Metastatic KRAS-Mutated mCRC